

## Declaration of Interest and Declaration of Confidentiality of ISoP Advisory Board members

This form consists of two parts, your personal details with biography, and the Public Declaration of Interests. It applies to the Executive Committee (EC) and Advisory Board members of the International Society of Pharmacovigilance.

Both parts of the form should be fully completed, signed, dated and return electronically to [administration@isoponline.org](mailto:administration@isoponline.org) with a short biography.

The Declaration of Interest and the biography will be published on isoponline.

### 1 Personal Details (please enclose your biography)

<b>First Name</b>	Manal
<b>Surname</b>	Younus
<b>Organisation</b>	MOH
<b>Country</b>	Iraq

I enclose my biography

I, [Manal Younus], do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below: NA

### 2 Public Declaration of Interests

If you have interests to declare, please do so under the relevant questions. If you have no interests to declare, please indicate that the appropriate field is non-applicable. Please specify the interests that you currently have or have had in the past 5 years.

<b>Title/Function</b>	<b>Period of activity (within past 5 years)</b>	<b>Company* or organisation**</b>	<b>Description of the activity</b>
<b>1. Employment with a pharmaceutical company or an organisation</b>			
Director of National PV Center	2016-now	MOH-Iraq	All aspects related to data collection, signal and risk management and communication.

CIOMS Executive Committee	2022-2025	CIOMS	Initiatives related to pv, drug safety and ethics.
2. Consultancy, advice or services with a pharmaceutical company or an organisation (including training)			
WHO	2021, 2022	Temporary consultant	As Bench-marking assessor
WHO	2020, 2021, 2022	Trainer	Capacity building regarding pv (medicines and COVID-10 vaccines)
Speaker in a conference	April 2022	Acino	presentation on combating substandard and falsified medicines.
Speaker in a conference	Jan 2022	Astellus	Presentation about pv. In Iraq.
Speaker in a conference	Nov.2021	Novo nordisk	presentation on combating substandard and falsified medicines.
Speaker in a conference	Sep 2021	Julphar	Presentation about pv.
Speaker in a conference	9 Nov.2019	Novo nordisk	presentation on understanding biosimilars
Advisory board	19 April 2019	Pfizer	Participation in one day activity covering the current concept of biosimilar and incomparable products
Symposium	14 Sept. 2018	Novartis	Presenting the role of pharmacovigilance in safety updates
Speaker in a conference	8 Dec. 2017	Novartis	Presenting the importance of integration of all regulatory activities.
3. Strategic advisory role, member of professional societies, affiliation or equivalent structure			
Elected Board Member and Scientific Committee Head	2021-2024	Syndicate of Iraqi Pharmacists (NGO)	Capacity building for the pharmacists working in Iraq. Regulating the pharmaceutical private sector.
IAPH- AMR committee member	2020 till date	International Society of Public Health	GHD EMPHNET Technical Team

4. Grant / research funding including sponsorships, fellowships, non-monetary			
NA	NA	NA	NA
5. Financial interests, direct shares of a pharmaceutical company, compensation, fees, honoraria (excluded investment trust without direct influence on shares)			
NA	NA	NA	NA
6. Patents			
NA	NA	NA	NA
7. Investigator (in a pharmaceutical industry instigated/sponsored clinical trial)			
NA	NA	NA	NA
8. Family member interest			
NA	NA	NA	NA
9. Any other interests or facts			
NA	NA	NA	NA

*\* Pharmaceutical company (includes supply or service companies which contribute to the research, development production and maintenance of a medicinal product)*

*\*\* An organisation includes governmental, international or non-profit organisations (outside ISoP)*

Should there be any change to the information provided above due to the fact that I acquire additional interests, I shall promptly notify ISoP and complete a new Declaration of Interests detailing the changes.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the ISoP website.

Signature: Manal Younus

Date: 10/10/2022